Glucose Transporter 1 (SLC2A1) and Vascular Endothelial Growth Factor A (VEGFA) Predict Survival After Resection of Colorectal Cancer Liver Metastasis
Goos, Jeroen A C M; de Cuba, Erienne M V; Coupé, Veerle M H; Diosdado, Begoña; Delis-Van Diemen, Pien M; Karga, Cemile; Beliën, Jeroen A M; Menke-Van der Houven van Oordt, C Willemien; Geldof, Albert A; Meijer, Gerrit A; Hoekstra, Otto S; Fijneman, Remond J A; DeCoDe PET Group; Lam, MGEH; Borel Rinkes, IHM; van Diest, PJ; van Hillegersberg, R; Kranenburg, OW
(2016) Annals of Surgery, volume 263, issue 1, pp. 138 - 145
(Article)
Abstract
OBJECTIVE: To investigate the individual and combined prognostic value of HIF1α, SLC2A1, and vascular endothelial growth factor A (VEGFA) in a multi-institutional cohort of patients with resected colorectal cancer liver metastasis (CRCLM). BACKGROUND: In the majority of patients with CRCLM, resection seems not to be curative, despite its curative intent.
... read more
Overexpression of hypoxia-inducible factor 1α (HIF1α), glucose transporter 1 (SLC2A1; also known as GLUT1), and VEGFA has been associated with tumor progression and poor prognosis of patients with colorectal cancer (CRC). METHODS: Tissue microarrays were generated using CRCLM and patient-matched primary CRC from patients who underwent CRCLM resection between 1990 and 2010. Prognostic value of HIF1α, SLC2A1, and VEGFA was determined by immunohistochemistry. A 500-fold cross-validated hazard rate ratio (HRRav) for overall survival was calculated. RESULTS: HIF1α, SLC2A1, and VEGFA expression could be evaluated in 328, 350, and 335 patients, respectively. High SLC2A1 expression was associated with good prognosis (HRRav, 0.67; P (HRR >1) < 0.01) and high VEGFA expression to poor prognosis (HRRav, 1.84; P (HRR < 1) = 0.02), also after multivariate analysis including established clinicopathological prognostic variables (HRRav, 0.67; P (HRR > 1) < 0.01 and HRRav, 1.50; P (HRR < 1) = 0.02, respectively). SLC2A1 showed prognostic value particularly in patients treated with systemic therapy (P < 0.01), whereas the prognostic value of VEGFA expression was mainly observed in patients not treated with systemic therapy (P < 0.01). Prognosis was especially poor in patients with both low SLC2A1 and high VEGFA expression (P < 0.01). HIF1α expression was not associated with survival. CONCLUSIONS: SLC2A1 and VEGFA expression are prognostic molecular biomarkers for patients with CRCLM with added value to established clinicopathological variables.
show less
Download/Full Text
The full text of this publication is not available.
Keywords: Colorectal Neoplasms, Glucose Transporter Type 1, VEGFA, Hypoxia-Inducible Factor 1, alpha Subunit, Liver Neoplasms, prognostic biomarker, SLC2A1, Survival Rate, Vascular Endothelial Growth Factor A, colorectal cancer, HIF1, liver metastasis, Journal Article, Research Support, Non-U.S. Gov't
ISSN: 0003-4932
Publisher: Lippincott Williams and Wilkins
(Peer reviewed)